BiondVax Pharmaceuticals Ltd represents the values of innovation, research excellence, and commitment to public health. With a strong corporate philosophy focused on developing and commercializing innovative vaccines, BiondVax aims to improve the lives of individuals and communities worldwide. The company is dedicated to advancing preventative medicine through its unique proprietary technology platform, M-001, which aims to enhance the effectiveness of influenza vaccines. BiondVax Pharmaceuticals Ltd is committed to addressing global health challenges and contributing to the well-being of society through continuous scientific advancements and collaborations with healthcare professionals and organizations.

BiondVax Pharmaceuticals Ltd is primarily present in Israel.

BiondVax Pharmaceuticals Ltd has achieved several significant milestones in its growth and development. Notably, the company successfully completed a Phase 2b clinical trial for their flagship product, M-001, a universal flu vaccine that has shown promising results in providing broad protection against multiple influenza strains. BiondVax also secured funding and support from prestigious institutions, such as the European Union's Horizon 2020 program. Additionally, they have received regulatory approvals to commence Phase 3 trials, indicating the potential for commercialization in the near future. These achievements demonstrate BiondVax's dedication to innovative research and development, positioning them as a promising player in the pharmaceutical industry.

BiondVax Pharmaceuticals Ltd is a leading biopharmaceutical company focused on developing and commercializing innovative immunomodulation therapies for infectious diseases. Founded in 2003, the company is committed to improving global public health through its cutting-edge technologies. BiondVax's core product, M-001, is a universal flu vaccine designed to provide broad protection against multiple influenza strains. With a strong emphasis on research and development, the company has reached significant milestones, including successful clinical trials and collaborations with prestigious partners. BiondVax Pharmaceuticals Ltd is renowned in the healthcare industry for its dedication to advancing preventive medicine solutions and tackling global health challenges.

The main competitors of BiondVax Pharmaceuticals Ltd in the market are other pharmaceutical companies operating in the field of vaccine development and production. Some notable competitors include Pfizer, Moderna, Johnson & Johnson, Novavax, and Sanofi. These companies are engaged in research and development of vaccines for various diseases and viruses. BiondVax Pharmaceuticals Ltd faces stiff competition in its efforts to develop innovative and effective vaccines, with each competitor striving to offer their own unique solutions to public health challenges.

BiondVax Pharmaceuticals Ltd primarily operates in the biopharmaceutical industry.

The business model of BiondVax Pharmaceuticals Ltd revolves around the development and commercialization of innovative vaccines for various viral diseases, with a particular focus on influenza. The company utilizes a proprietary technology platform, M-001, which enables the creation of a universal flu vaccine that offers broad protection against multiple strains and subtypes of the influenza virus. BiondVax Pharmaceuticals works towards conducting clinical trials, obtaining regulatory approvals, and partnering with global pharmaceutical companies for the distribution and marketing of its vaccines worldwide.

De BiondVax Pharmaceuticals K/W is -364,44.

De BiondVax Pharmaceuticals KUV is 0.

De AlleAktien Kwaliteitsscore voor BiondVax Pharmaceuticals is 1/10.

De omzet kan momenteel niet worden berekend voor BiondVax Pharmaceuticals.

De verwachte BiondVax Pharmaceuticals winst is -3,80 mln. ILS.

BiondVax Pharmaceuticals Ltd is a leading biopharmaceutical company specializing in the development and production of influenza vaccines. The company is headquartered in Jerusalem, Israel and operates subsidiaries in the USA and Europe. BiondVax Pharmaceuticals' business model focuses on innovative technologies and extensive research and development to meet the market demand for safe and effective influenza vaccines. The company works closely with leading scientific institutions and experts to develop cutting-edge solutions for influenza prevention. One of BiondVax Pharmaceuticals' key products is the Universal Flu Vaccine Candidate (M-001), a vaccine candidate that has the potential to significantly increase protection against seasonal and pandemic influenza viruses. M-001 is an innovative vaccine candidate based on peptide-based immune system stimulation technology, allowing for a broader range of influenza strains to be covered. In addition, BiondVax Pharmaceuticals also offers other products and services including the production of recombinant proteins, analysis of protein interactions, and protein design solutions. The company has extensive experience in the production, quality control, and scaling up of novel influenza vaccines. BiondVax Pharmaceuticals has also specialized in the development of technologies to enhance existing vaccines. This includes technological innovations aimed at improving the effectiveness of influenza vaccines in older adults and other high-risk groups. The company's technology is also intended to improve the duration and strength of immunity after vaccination. To realize its business model, BiondVax Pharmaceuticals has established an extensive research and development department. The company also collaborates closely with universities, research institutions, and other biotech companies to collectively develop new therapeutic solutions. The company also has a clear growth strategy. BiondVax Pharmaceuticals plans to expand into new geographic markets while also expanding its product range to meet the growing demand for vaccines and prophylactic treatments. In conclusion, BiondVax Pharmaceuticals Ltd is a leading biopharmaceutical company that focuses on the development and production of novel influenza vaccines. Through innovative technologies and extensive research and development, BiondVax Pharmaceuticals is able to deliver market-leading solutions that meet the demand for safe and effective vaccines. With a clear growth strategy and a strong commitment to research and development, BiondVax Pharmaceuticals will undoubtedly continue to make significant contributions to the healthcare industry in the coming years.

BiondVax Pharmaceuticals keert een dividend van 0 ILS uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor BiondVax Pharmaceuticals of het bedrijf keert geen dividend uit.

De ISIN van BiondVax Pharmaceuticals is US09073Q1058.

Het WKN van BiondVax Pharmaceuticals is A14TFZ.

De ticker van BiondVax Pharmaceuticals is BVXV.

Binnen de laatste 12 maanden betaalde BiondVax Pharmaceuticals een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal BiondVax Pharmaceuticals naar verwachting een dividend van 0 ILS betalen.

De dividendrendement van BiondVax Pharmaceuticals is momenteel .

BiondVax Pharmaceuticals betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

BiondVax Pharmaceuticals betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 ILS verwacht. Dit komt overeen met een dividendrendement van 0 %.

BiondVax Pharmaceuticals wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van BiondVax Pharmaceuticals van 7-10-2024 ter hoogte van 0 ILS te ontvangen, moest je het aandeel voor de ex-datum op 7-10-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 7-10-2024.

In het jaar 2023 heeft BiondVax Pharmaceuticals 0 ILS aan dividenden uitgekeerd.

De dividenden van BiondVax Pharmaceuticals worden in ILS uitgekeerd.